What Is Bufo? The Toad Behind 5-MeO-DMT
Bufo is the common name for 5-MeO-DMT — a short-acting psychedelic found in the venom of the Sonoran Desert toad, and now more often made synthetically. In treatment settings it is usually offered after ibogaine, not instead of…
5-MeO-DMT · The Bufo Question
What is bufo, and why does it follow ibogaine?
Bufo is the common name for 5-MeO-DMT — a short-acting psychedelic found in the venom of the Sonoran Desert toad, and now more often made synthetically. In treatment settings it is usually offered after ibogaine, not instead of it.
Clinically reviewed by Christopher Diviaio, LCSW · Last updated 5 September 2026
The single biggest difference
How long does bufo actually last?
A vaporised 5-MeO-DMT session usually runs 15–45 minutes end to end, with onset in seconds and the peak inside the first five. Ibogaine runs on a completely different clock — 24 to 36 hours of active experience, then days of recovery. That difference is the whole reason the two are sequenced rather than swapped.
Bars drawn to the same scale — 45 minutes is roughly 3% of a 24-hour ibogaine session. Durations are typical ranges, not guarantees; individual response varies and is one of the things screening exists to anticipate.
Where it comes from
A toad, a gland, and a conservation problem.
5-MeO-DMT occurs naturally in the parotoid gland secretion of Bufo alvarius (also classified Incilius alvarius), the Sonoran Desert toad of northern Mexico and the south-western United States.
It is also produced synthetically — and increasingly that is what responsible programmes use. Synthetic 5-MeO-DMT is the same molecule at a known purity and dose, and it takes the pressure off a wild animal that is collected, milked and, in the worst practice, harmed. If a programme cannot tell you which one it uses, that is an answer in itself.
This is one of the things we check against the standard. The PC Standard covers sourcing alongside screening and monitoring.
The sequence
Why bufo usually comes after ibogaine.
Most programmes that offer both run them in order, days apart. The reasoning is practical rather than mystical.
Screening first
Medical and psychiatric review, including current medications. Serotonergic antidepressants matter here.
Ibogaine
The long session. Interrupts withdrawal and does the heavy pharmacological work over 24–36 hours.
Recovery days
Rest, monitoring and sleep. Nothing is scheduled into this window; the body is still clearing.
Bufo, then integration
A short session once stable, framed as closure — followed by the integration work that decides whether any of it holds.
What it costs
How much does bufo cost?
Two answers, depending on how you get there. Inside an ibogaine programme a 5-MeO-DMT session is normally included in the fee. Bought on its own — outsourced to an external facilitator — a single session typically runs $300–$1,500.
Included
Part of the $5,000–$15,000 ibogaine programme fee, alongside screening, the ibogaine session, monitoring and aftercare. This is the usual arrangement at facilities that offer both.
$300–$1,500
Some programmes do not run 5-MeO-DMT in house and arrange it externally. Billed separately, a single session usually lands in this range — and this is the tier where screening, monitoring and integration are most often absent.
What the price is really telling you is how much supervision comes with it. At the lower end you are usually paying for the session alone — one dose, often without medical screening or any integration afterwards. Higher figures generally buy physician screening, monitoring during the session, and structured follow-up. Ask any programme which of those are included before you compare two numbers. That is exactly what we look at when we visit.
Synthetic or toad-derived
What actually differs between the two.
| Synthetic 5-MeO-DMT | Toad-derived secretion | |
|---|---|---|
| Composition | A single known compound | A mixture — 5-MeO-DMT plus bufotenin and other alkaloids |
| Dose accuracy | Measurable by weight | Varies by animal, season and preparation |
| Animal impact | None | Wild collection pressure on a desert species |
| What to ask | “Which do you use, and how is the dose determined?” — a programme that cannot answer plainly is telling you something. | |
Cited research: Uthaug et al., Psychopharmacology 236(9):2653–2666, 2019 — doi:10.1007/s00213-019-05236-w. Read it with its limits in mind: 42 participants, no control group, a naturalistic field setting rather than a clinic, and self-reported outcomes. It reports sustained improvements in satisfaction with life and reductions in depression, anxiety and stress ratings at four weeks, and the authors themselves frame it as grounds for further research — not as evidence of a treatment.
The confusion worth clearing up first
Is bufo the same as the cane toad?
No — and it matters. Bufo comes from the Sonoran Desert toad, Incilius alvarius. The cane toad, Rhinella marina, is the invasive species in Florida that poisons dogs. It contains no 5-MeO-DMT. Both get called “bufo toad” in everyday speech, which is why searching the term returns pest-control advice alongside psychedelic medicine.
Sonoran Desert toad — Incilius alvarius
Native to the Sonoran Desert of northern Mexico and the US Southwest. Its parotoid glands produce a secretion containing 5-MeO-DMT alongside bufotenin and a family of related compounds. This is the animal people mean when they talk about a bufo ceremony.
You will still see it written as Bufo alvarius. That was the original classification and it is the name most of the research was published under, so both appear in the literature. Incilius alvarius is the current accepted name.
Cane toad — Rhinella marina
Introduced to Florida, Australia and elsewhere, where it is a serious invasive pest. Its secretion contains bufotoxins and bufotenin but not 5-MeO-DMT, and it is genuinely dangerous — it kills pets that mouth it.
Attempts to use cane toad secretion as a psychedelic have caused poisonings and deaths. Nothing on this page applies to it. If you are here because a toad is threatening your dog, your state wildlife agency is the right resource, not us.
We lead with this because almost nobody else does, and the two animals are confused constantly — including by people who then look for the wrong information entirely.
What the material actually is
What is toad venom, exactly?
“Toad venom” is the dried secretion from the Sonoran Desert toad’s glands. It is not a single compound — it is a mixture, of which 5-MeO-DMT is the psychoactive part people are seeking. That mixture is exactly why most responsible providers have moved away from it.
The secretion also contains bufotenin and a range of other alkaloids whose proportions vary from animal to animal, season to season. There is no way to know the composition of a given sample by looking at it, which means there is no reliable way to know what someone is actually taking.
Synthetic 5-MeO-DMT solves that. It is the same molecule, produced to a known purity, which allows a provider to work from a consistent starting point rather than an unknown one. It also takes the animal out of the process entirely — wild populations have come under real pressure from demand, and a toad is not a renewable supply chain.
This is why, when we look at a provider, whether they use synthetic material is one of the things we ask about. It is a reasonable question to ask yourself, and a provider who cannot answer it clearly has told you something.
The legal position, plainly
Is bufo legal?
No. 5-MeO-DMT is a Schedule I controlled substance in the United States, whether it comes from a toad or a laboratory. That is why legitimate programmes operate in countries where it is not scheduled.
Schedule I is the most restrictive category, and it applies to possession and supply alike. Being in a ceremonial or therapeutic setting is not a legal defence in the US. Mexico is the most common destination for supervised programmes, and it is where the ibogaine clinics we visit are located.
Travelling abroad for treatment is legal for US citizens. Bringing the substance home is not, and nobody credible will offer to. If a provider inside the United States offers you a bufo session, that is not a grey area — and it tells you how they are likely to handle everything else.
This is general information about legal status, not legal advice. Laws change, and they differ by country and by state.
Beyond the field study above
What does the wider research on 5-MeO-DMT show?
Two independent reviews have now assessed the whole literature. Both reach the same encouraging conclusion: the signal is real and consistent, the pharmacology is well understood, and controlled trials are the next step.
A 2021 review in the Journal of Psychopharmacology synthesised the available research and found that epidemiological studies consistently report profound alterations in consciousness with potential beneficial long-term effects on mental health and wellbeing. Its authors concluded that further clinical exploration is warranted, using the same precautions applied to other classic psychedelics.
Ermakova AO, Dunbar F, Rucker J, Johnson MW. J Psychopharmacol 2021;36(3):273–294. DOI 10.1177/02698811211050543 · PMID 34666554. Narrative review — synthesis of existing studies, not new trial data.
A 2022 clinical pharmacology review in the Journal of Neurochemistry described how the compound works — it acts on the serotonin system, with highest affinity for the 5-HT1A receptor — and noted that single exposure has been associated with rapid and sustained reductions in symptoms of depression, anxiety and stress across observational studies and surveys. It also makes a practical point: because the experience is short, 5-MeO-DMT is unusually well suited to careful clinical study compared with longer-acting psychedelics.
Reckweg JT, Uthaug MV, Szabo A, Davis AK, Lancelotta R, Mason NL, Ramaekers JG. J Neurochem 2022;162(1):128–146. DOI 10.1111/jnc.15587 · PMID 35149998. Review.
What’s next: controlled trials in patients. Several pharmaceutical groups are developing 5-MeO-DMT formulations, most aimed at depression. That work will answer what observational research cannot — and the fact that it is underway at all reflects how seriously these early results are being taken.
Honestly, and without hedging
Is bufo safe, and who is it not for?
The published safety picture is reassuring in supervised settings and poor in unsupervised ones. The difference is not the molecule — it is screening, the person sitting with you, and what happens if something goes wrong.
The experience is short but it is not gentle. Ego dissolution — the temporary loss of the sense of being a separate self — is the point for many people and is frightening for others. Some people vomit. Some are physically overwhelmed for a few minutes. A facilitator’s job during that window is to keep you safe and let it pass.
Where the real risk sits
- Unknown material. Raw secretion of unknown composition, taken outside a medical setting, is the single most common thread in reports of serious harm.
- No screening. Personal and family psychiatric history matters here, particularly any history of psychosis or bipolar disorder. So does your current medication list — serotonergic antidepressants are a specific interaction concern and are the sort of thing a provider must review before, not after.
- Nobody trained in the room. A short experience still needs someone present who knows what they are looking at and can act.
- Nothing afterwards. A profound experience with no integration support is where a lot of the disappointment comes from — not from the session itself.
Every provider we recommend is screened against our Provider Standard™, and, wherever we can, we visit them. Screening is a step in that process, not an afterthought — and if your history means bufo is not appropriate, we would rather tell you that than place you.
This is educational information and not medical advice. Whether any treatment is appropriate for you is a decision for qualified clinicians who have reviewed your history.
Common questions
Bufo and 5-MeO-DMT — frequently asked
Is bufo the same thing as 5-MeO-DMT?
Is bufo legal?
Is it the same as regular DMT?
Can I do bufo if I take antidepressants?
Is bufo charged separately from ibogaine?
Do I have to do ibogaine to do bufo?
Not sure whether bufo belongs in your plan?
We will talk it through honestly, including the cases where the answer is no. We hold every clinic we recommend to our published standard, and we will tell you what we saw.
Related on this site: 5-MeO-DMT guide · 5-MeO-DMT retreats · ibogaine and 5-MeO-DMT combination · ibogaine safety guide · what we do
Sources and further reading
Speak with an advisor.
A confidential conversation about your situation and the options actually worth considering — from people who visit every provider they recommend.